Evidence map›Paper›PMID 25882602›Full record

ArticleBreast cancer research : BCR2015

Tumor expression, plasma levels and genetic polymorphisms of the coagulation inhibitor TFPI are associated with clinicopathological parameters and survival in breast cancer, in contrast to the coagulation initiator TF.

Mari Tinholt, Hans Kristian Moen Vollan, Kristine Kleivi Sahlberg, Sandra Jernström, Fatemeh Kaveh, Ole Christian Lingjærde, Rolf Kåresen, Torill Sauer, Vessela Kristensen, Anne-Lise Børresen-Dale and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Breast cancer research : BCR, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 35 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Observational
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Mari TinholtDepartment of Medical Genetics, Oslo University Hospital and University of Oslo, BOX 4956, Nydalen, Oslo, N-0424, Norway. mari.tinholt@medisin.uio.no.
Hans Kristian Moen VollanDepartment of Genetics, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, Oslo, Norway. hans.kristian.vollan@me.com.
Kristine Kleivi SahlbergDepartment of Genetics, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, Oslo, Norway. kristine.kleivi@gmail.com.
Sandra JernströmDepartment of Genetics, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, Oslo, Norway. Sandra.Nyberg@rr-research.no.
Fatemeh KavehDepartment of Medical Genetics, Oslo University Hospital and University of Oslo, BOX 4956, Nydalen, Oslo, N-0424, Norway. fatemeh.kaveh@medisin.uio.no.
Ole Christian LingjærdeThe K.G. Jebsen Center for Breast Cancer Research, Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway. ole@ifi.uio.no.
Rolf KåresenInstitute of Clinical Medicine, University of Oslo, Oslo, Norway. rolf.karesen@medisin.uio.no.
Torill SauerDepartment of Pathology, Akershus University Hospital, Lørenskog, Norway. torill.sauer@medisin.uio.no.
Vessela KristensenDepartment of Genetics, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, Oslo, Norway. v.n.kristensen@medisin.uio.no.
Anne-Lise Børresen-DaleDepartment of Genetics, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, Oslo, Norway. a.l.borresen-dale@medisin.uio.no.
Per Morten SandsetDepartment of Haematology and Research Institute of Internal Medicine, Oslo University Hospital, Oslo, Norway. p.m.sandset@medisin.uio.no.
Nina IversenDepartment of Medical Genetics, Oslo University Hospital and University of Oslo, BOX 4956, Nydalen, Oslo, N-0424, Norway. nina.iversen@medisin.uio.no.
Oslo University Hospital · NOUniversity of Oslo · NOAkershus University Hospital · NO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionHypercoagulability in malignancy increases the risk of thrombosis, but is also involved in cancer progression. Experimental studies suggest that tissue factor (TF) and tissue factor pathway inhibitor (TFPI) are involved in cancer biology as a tumor- promoter and suppressor, respectively, but the clinical significance is less clear. Here, we aimed to investigate the clinical relevance of TF and TFPI genetic and phenotypic diversity in breast cancer.

methodsThe relationship between tumor messenger RNA (mRNA) expression and plasma levels of TF and TFPI (α and β), tagging single nucleotide polymorphisms (tagSNPs) in F3 (TF) (n=6) and TFPI (n=18), and clinicopathological characteristics and molecular tumor subtypes were explored in 152 treatment naive breast cancer patients. The effect of tumor expressed TF and TFPIα and TFPIβ on survival was investigated in a merged breast cancer dataset of 1881 patients.

resultsProgesterone receptor negative patients had higher mRNA expression of total TFPI (α+β) (P=0.021) and TFPIβ (P=0.014) in tumors. TF mRNA expression was decreased in grade 3 tumors (P=0.003). In plasma, total TFPI levels were decreased in patients with larger tumors (P=0.013). SNP haplotypes of TFPI, but not TF, were associated with specific clinicopathological characteristics like tumor size (odds ratio (OR) 3.14, P=0.004), triple negativity (OR 2.4, P=0.004), lymph node spread (OR 3.34, P=0.006), and basal-like (OR 2.3, P=0.011) and luminal B (OR 3.5, P=0.005) molecular tumor subtypes. Increased expression levels of TFPIα and TFPIβ in breast tumors were associated with better outcome in all tumor subtypes combined (P=0.007 and P=0.005) and in multiple subgroups, including lymph node positive subjects (P=0.006 and P=0.034).

conclusionsThis study indicates that genetic and phenotypic variation of both TFPIα and TFPIβ, more than TF, are markers of cancer progression. Together with the previously demonstrated tumor suppressor effects of TFPI, the beneficial effect of tumor expressed TFPI on survival, renders TFPI as a potential anticancer agent, and the clinical significance of TFPI in cancer deserves further investigation.

Indexed as

Gene ExpressionPolymorphism, Single NucleotideAdultAgedAllelesBiomarkers, TumorBreast NeoplasmsFemaleGenetic Association StudiesGenotypeHaplotypesHumansLipoproteinsMiddle AgedNeoplasm GradingNeoplasm MetastasisBiomarkers, Tumorlipoprotein-associated coagulation inhibitorLipoproteinsRNA, MessengerThromboplastin

Identifiers

PMID25882602
PMCPMC4423106
OpenAlexW2129845116

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.